211 related articles for article (PubMed ID: 27517917)
1. The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer.
Cabello P; Pineda B; Tormo E; Lluch A; Eroles P
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27517917
[TBL] [Abstract][Full Text] [Related]
2. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer.
Zhang B; Liu XX; He JR; Zhou CX; Guo M; He M; Li MF; Chen GQ; Zhao Q
Carcinogenesis; 2011 Jan; 32(1):2-9. PubMed ID: 20952513
[TBL] [Abstract][Full Text] [Related]
3. MiRNA-26a inhibits myocardial infarction-induced apoptosis by targeting PTEN via JAK/STAT pathways.
Wang J; Feng Q; Liang D; Shi J
Cells Dev; 2021 Mar; 165():203661. PubMed ID: 33993982
[TBL] [Abstract][Full Text] [Related]
4. MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1.
Gao J; Li L; Wu M; Liu M; Xie X; Guo J; Tang H; Xie X
PLoS One; 2013; 8(6):e65138. PubMed ID: 23750239
[TBL] [Abstract][Full Text] [Related]
5. Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: pivotal role of superoxide dismutase (SOD).
Sharma P; Kumar S
Cell Oncol (Dordr); 2018 Dec; 41(6):637-650. PubMed ID: 30088260
[TBL] [Abstract][Full Text] [Related]
6. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.
Tormo E; Adam-Artigues A; Ballester S; Pineda B; Zazo S; González-Alonso P; Albanell J; Rovira A; Rojo F; Lluch A; Eroles P
Sci Rep; 2017 Jan; 7():41309. PubMed ID: 28120942
[TBL] [Abstract][Full Text] [Related]
7. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
Bao B; Wang Z; Ali S; Ahmad A; Azmi AS; Sarkar SH; Banerjee S; Kong D; Li Y; Thakur S; Sarkar FH
Cancer Prev Res (Phila); 2012 Mar; 5(3):355-64. PubMed ID: 22086681
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-26a regulates cerebral ischemia injury through targeting PTEN.
Guo XL; Liang H; Sun Y; Wang CB
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):7033-7041. PubMed ID: 31486504
[TBL] [Abstract][Full Text] [Related]
9. Metformin inhibits HaCaT cell viability via the miR-21/PTEN/Akt signaling pathway.
Deng Y; Ma W
Mol Med Rep; 2018 Mar; 17(3):4062-4066. PubMed ID: 29286158
[TBL] [Abstract][Full Text] [Related]
10. miR-26a promotes hepatocellular carcinoma invasion and metastasis by inhibiting PTEN and inhibits cell growth by repressing EZH2.
Zhao WT; Lin XL; Liu Y; Han LX; Li J; Lin TY; Shi JW; Wang SC; Lian M; Chen HW; Sun Y; Xu K; Jia JS; Luo RC; Xiao D
Lab Invest; 2019 Oct; 99(10):1484-1500. PubMed ID: 31201367
[TBL] [Abstract][Full Text] [Related]
11. MiR-26a-5p Heightens Breast Cancer Cell Sensitivity to Paclitaxel via Targeting Flap Endonuclease 1.
Cai Y; Zhang T; Chen G; Liu C
Ann Clin Lab Sci; 2023 Jan; 53(1):116-125. PubMed ID: 36889769
[TBL] [Abstract][Full Text] [Related]
12. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
Zhong S; Li W; Chen Z; Xu J; Zhao J
Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-26a-5p inhibits breast cancer cell growth by suppressing RNF6 expression.
Huang ZM; Ge HF; Yang CC; Cai Y; Chen Z; Tian WZ; Tao JL
Kaohsiung J Med Sci; 2019 Aug; 35(8):467-473. PubMed ID: 31063232
[TBL] [Abstract][Full Text] [Related]
14. MiR-26a inhibits proliferation and migration of HaCaT keratinocytes through regulating PTEN expression.
Yu N; Yang Y; Li X; Zhang M; Huang J; Wang X; Long X
Gene; 2016 Dec; 594(1):117-124. PubMed ID: 27613140
[TBL] [Abstract][Full Text] [Related]
15. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
[TBL] [Abstract][Full Text] [Related]
16. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.
Jansen MP; Reijm EA; Sieuwerts AM; Ruigrok-Ritstier K; Look MP; Rodríguez-González FG; Heine AA; Martens JW; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2012 Jun; 133(3):937-47. PubMed ID: 22094936
[TBL] [Abstract][Full Text] [Related]
17. Oxidized Low Density Lipoprotein-Induced Atherogenic Response of Human Umbilical Vascular Endothelial Cells (HUVECs) was Protected by Atorvastatin by Regulating miR-26a-5p/Phosphatase and Tensin Homolog (PTEN).
Jia Z; An L; Lu Y; Xu C; Wang S; Wang J; Teng X
Med Sci Monit; 2019 Dec; 25():9836-9843. PubMed ID: 31865360
[TBL] [Abstract][Full Text] [Related]
18. MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.
Chen J; Xu Y; Tao L; Pan Y; Zhang K; Wang R; Chen LB; Chu X
Cell Physiol Biochem; 2017; 41(2):583-597. PubMed ID: 28214878
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Long Noncoding RNA HOTAIR and EZH2 Induces Apoptosis and Inhibits Proliferation, Invasion, and Migration of Human Breast Cancer Cells.
Han L; Zhang HC; Li L; Li CX; Di X; Qu X
Cancer Biother Radiopharm; 2018 Aug; 33(6):241-251. PubMed ID: 30048163
[TBL] [Abstract][Full Text] [Related]
20. The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.
Fragni M; Bonini SA; Bettinsoli P; Bodei S; Generali D; Bottini A; Spano PF; Memo M; Sigala S
Naunyn Schmiedebergs Arch Pharmacol; 2016 May; 389(5):529-38. PubMed ID: 26905520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
